ADDF reflects on Eli Lilly’s donanemab
Company’s phase 3 research showed the importance of running biomarker-powered clinical trials
Read More
Tag: donanemab
Lilly’s donanemab slows decline in Phase II Alzheimer’s study
Alzheimer’s Drug Discovery Foundation says results are ‘promising’
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
